0R15 9080.0 -2.7837% 0R1E 9565.0 5.7373% 0M69 None None% 0R2V 233.75 12.1103% 0QYR 1560.0 -0.7634% 0QYP 409.5 0.0% 0RUK None None% 0RYA 1576.0 1.2203% 0RIH 190.65 0.0% 0RIH 190.3 -0.1836% 0R1O 218.55 9948.2759% 0R1O None None% 0QFP 10717.21 112.6431% 0M2Z 295.8502 1.1713% 0VSO 32.02 -10.0688% 0R1I None None% 0QZI 595.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 226.55 0.1373%
Last update at 2025-01-14T18:53:00Z
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Sun 15 Sep 24, 11:21 AM3 Biotech Stocks That Could Have Investors Grinning Soon
Fri 02 Aug 24, 05:54 PMCan These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Sat 20 Jul 24, 01:30 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -59.98700M | -49.65000M | -39.75800M | -68.83900M | -18.08500M |
| Minority interest | - | 0.00000M | 0.52M | 14.12M | 14.32M |
| Net income | -60.34500M | -50.15800M | -40.57100M | -68.81900M | -17.71100M |
| Selling general administrative | 22.41M | 19.55M | 9.00M | 8.66M | 3.90M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | 1.00M | - | - | - |
| Reconciled depreciation | 1.03M | 0.51M | 0.39M | 0.20M | 0.07M |
| Ebit | -63.06100M | -50.37200M | -37.02500M | -70.19700M | -18.45500M |
| Ebitda | -62.02900M | -49.86000M | -36.63100M | -70.00200M | -18.39000M |
| Depreciation and amortization | 1.03M | 0.51M | 0.39M | 0.20M | 0.07M |
| Non operating income net other | 2.04M | - | - | - | - |
| Operating income | -62.02900M | -49.86000M | -37.02500M | -70.19700M | -18.45500M |
| Other operating expenses | 62.03M | 50.86M | 37.02M | 70.20M | 18.45M |
| Interest expense | -2.04200M | 0.72M | 2.21M | 1.57M | 0.00000M |
| Tax provision | 0.36M | 0.51M | 0.81M | -0.02000M | -0.06700M |
| Interest income | 2.11M | 0.17M | 0.06M | 1.20M | 0.33M |
| Net interest income | 2.11M | 0.17M | 0.06M | 1.20M | 0.33M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.36M | 0.51M | 0.81M | -0.02000M | -0.06700M |
| Total revenue | 0.00000M | 1.00M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 62.03M | 50.86M | 37.02M | 70.20M | 18.45M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 2.04M | 0.21M | -2.73300M | 1.36M | 0.04M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -60.34500M | -50.15800M | -40.57100M | -68.81900M | -18.01800M |
| Net income applicable to common shares | -60.34500M | -50.15800M | -29.35200M | -68.61100M | -17.71100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 268.52M | 287.03M | 168.07M | 92.29M | 23.90M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.99M | 2.07M | 0.95M | 0.33M | 0.46M |
| Total liab | 13.15M | 10.08M | 7.77M | 23.70M | 19.70M |
| Total stockholder equity | 255.37M | 276.94M | 160.30M | 68.59M | 4.21M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 7.62M | 6.16M | 4.69M | 8.17M | 3.31M |
| Common stock | 0.00600M | 0.00500M | 0.00300M | - | - |
| Capital stock | 0.00600M | 0.00500M | 0.00300M | 186.03M | 94.97M |
| Retained earnings | -332.62800M | -242.41800M | -182.07300M | -131.91500M | -91.86200M |
| Other liab | - | 1.07M | 0.95M | 0.88M | 0.63M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.04M | 0.09M | 0.25M | 0.72M |
| Cash | 79.93M | 143.24M | 47.70M | 74.85M | 12.33M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 11.94M | 8.47M | 6.82M | 22.82M | 4.95M |
| Current deferred revenue | 1.21M | - | - | 0.84M | - |
| Net debt | -79.32300M | -142.03000M | -47.69900M | -61.97400M | -12.32700M |
| Short term debt | 0.60M | 0.66M | - | 12.88M | - |
| Short long term debt | - | - | - | 12.88M | - |
| Short long term debt total | 0.60M | 1.21M | - | 12.88M | - |
| Other stockholder equity | 588.01M | 520.18M | 174.64M | 14.60M | 1.21M |
| Property plant equipment | - | 0.76M | 1.05M | 1.18M | 0.96M |
| Total current assets | 267.43M | 285.19M | 166.93M | 90.87M | 22.22M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 276.94M | 172.16M | -117.44100M | -90.76000M |
| Short term investments | 183.51M | 139.88M | 118.28M | 0.00000M | 7.32M |
| Net receivables | - | - | - | 12.72M | - |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | 2.97M | - |
| Accounts payable | 2.52M | 1.65M | 2.13M | 0.94M | 1.64M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.01900M | -0.82200M | -0.33800M | -0.12400M | -0.10600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00500M | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -242.41800M | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.06M | 0.04M | 0.09M | 0.25M | 0.72M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1.08M | 1.84M | 1.14M | 1.42M | 1.68M |
| Capital lease obligations | 0.60M | 1.21M | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -21.99700M | -119.35600M | 7.28M | -2.95600M | -4.53200M |
| Change to liabilities | 0.69M | 1.73M | -0.45300M | 0.63M | 0.49M |
| Total cashflows from investing activities | -22.27200M | -119.69600M | 6.69M | -3.85600M | -4.77600M |
| Net borrowings | 0.24M | -12.88000M | 16.88M | 0.06M | 0.06M |
| Total cash from financing activities | 167.09M | 134.39M | 85.52M | 0.06M | 99.76M |
| Change to operating activities | -0.31500M | -3.15200M | 6.21M | 1.15M | -0.98600M |
| Net income | -60.34500M | -50.15800M | -40.57100M | -68.81900M | -18.01800M |
| Change in cash | 95.54M | -27.15500M | 62.48M | -70.14700M | 77.02M |
| Begin period cash flow | 47.70M | 74.85M | 12.38M | 82.52M | 5.50M |
| End period cash flow | 143.24M | 47.70M | 74.85M | 12.38M | 82.52M |
| Total cash from operating activities | -49.10900M | -41.82700M | -29.80900M | -66.22200M | -18.07100M |
| Issuance of capital stock | 167.25M | 136.36M | 69.38M | 0.00000M | 87.65M |
| Depreciation | 1.03M | 0.51M | 0.39M | 0.20M | 0.07M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | - | - | - |
| Sale purchase of stock | 0.24M | - | - | - | - |
| Other cashflows from financing activities | -0.40100M | 10.91M | 16.14M | 0.06M | 99.76M |
| Change to netincome | 10.77M | 9.24M | -5.91100M | 0.33M | -0.07300M |
| Capital expenditures | 0.28M | 0.34M | 0.58M | 0.90M | 0.24M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | -0.71000M | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 95.71M | - | - | - | - |
| Change in working capital | -1.03700M | -1.42500M | 5.06M | 1.77M | -0.35200M |
| Stock based compensation | 10.77M | 8.15M | 1.69M | 0.67M | 0.23M |
| Other non cash items | 0.08M | 0.88M | 2.92M | -0.04000M | -0.30700M |
| Free cash flow | -49.38400M | -42.16700M | -30.39300M | -67.12200M | -18.31500M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals Inc |
-0.1 2.08% | 4.70 | - | - | 302.64 | 1.30 | 337.47 | -0.6833 |
| NVO Novo Nordisk A/S |
-3.705 4.38% | 80.92 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-2.8 3.34% | 80.95 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.13 0.27% | 414.50 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-18.615 2.60% | 698.28 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404
| Name | Title | Year Born |
|---|---|---|
| Mr. Senthil Vel Sundaram | CEO & Director | 1978 |
| Dr. Erin Quirk M.D. | Pres & Head of R&D | 1971 |
| Mr. Seokho Yoon Esq. | COO, Gen. Counsel & Sec. | 1978 |
| Dr. Weidong Zhong Ph.D. | Co-Founder & Exec. Officer | 1966 |
| Dr. Mark Joseph Vignola | CFO & Treasurer | 1978 |
| Dr. Jeffrey R. Jasper Ph.D. | Sr. VP & Head of Research | NA |
| Ms. Diana Chung | Sr. VP & Chief Devel. Officer | NA |
| Dr. Kerry Russell M.D., Ph.D. | Chief Medical Officer | NA |
| Dr. Erin Quirk M.D. | President & Head of Research & Development | 1971 |
| Mr. Seokho Yoon Esq. | COO, General Counsel & Secretary | 1978 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...